You have 7 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

resistance to imatinib

Showing 26 - 50 of 8,584
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • +2 more
    • (no location specified)
    Jul 15, 2022

    Second-line Pharmacotherapy Patterns and Outcomes of Advanced

    Not yet recruiting
    • Gastrointestinal Stromal Tumors
      • Guangzhou, Guangdong, China
        The first affiliated hospital,Sun yat-sen university
      Jun 30, 2022

      Leukemia, Myeloid, Chronic-Phase Trial in Germany (Ponatinib)

      Active, not recruiting
      • Leukemia, Myeloid, Chronic-Phase
      • Halle (Saale), Saxony-Anhalt, Germany
      • +9 more
      Sep 9, 2022

      Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

      Active, not recruiting
      • Acute Lymphoblastic Leukemia, Adult
      • +2 more
      • Ponatinib 15 MG Oral Tablet
      • Brno, Czechia
      • +6 more
      Nov 30, 2022

      Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

      Completed
      Has Results
      • Chronic Myeloid Leukemia
      • Omacetaxine mepesuccinate
      • Los Angeles, California
      • +31 more
      Nov 11, 2021

      CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

      Recruiting
      • CML
      • +3 more
      • Asciminib add-on
      • +3 more
      • Augusta, Georgia
      • +46 more
      Jan 23, 2023

      Chronic GVHD Trial in Israel, Italy (nilotinib)

      Completed
      • Chronic Graft Versus Host Disease
      • Tel Hashomer, Israel
      • +11 more
      Aug 19, 2021

      Gastrointestinal Stromal Tumors Trial in Seoul (Paclitaxel)

      Recruiting
      • Gastrointestinal Stromal Tumors
      • Seoul, Korea, Republic of
        Asan Medical Center
      Dec 30, 2022

      Chronic Myeloid Leukemia (CML) Trial in Italy (Ponatinib 15mg QD, Ponatinib 30mg QD)

      Not yet recruiting
      • Chronic Myeloid Leukemia (CML)
      • Ponatinib 15mg QD
      • Ponatinib 30mg QD
      • Cagliari, Italy
      • +12 more
      Jan 31, 2021

      Acute Lymphoblastic Leukemia, Adult Trial (Ponatinib, Blinatumomab, Imatinib)

      Not yet recruiting
      • Acute Lymphoblastic Leukemia, Adult
      • (no location specified)
      Dec 28, 2020

      Chronic Myeloid Leukemia Trial in Italy (Nilotinib)

      Completed
      • Chronic Myeloid Leukemia
      • Ascoli Piceno, Italy
      • +21 more
      Jan 3, 2022

      Metastatic or Unresectable Gastrointestinal Stromal Tumors

      Not yet recruiting
      • Gastrointestinal Stromal Tumors
      • +2 more
        • (no location specified)
        Jul 16, 2022

        Mesothelioma, Malignant Trial in Rozzano (Gemcitabine, Imatinib mesylate)

        Completed
        • Mesothelioma, Malignant
        • Rozzano, MI, Italy
          Istituto Clinico Humanitas
        Jan 20, 2021

        Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies Trial run by the

        Not yet recruiting
        • Inherited Bone Marrow Failure Syndrome
        • Familial Platelet Disorder With Predisposition to Myeloid Malignancies
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Oct 20, 2023

        Leukemia, Acute Lymphoblastic Trial in Worldwide (Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab

        Recruiting
        • Leukemia, Acute Lymphoblastic
        • Omitted Doxorubicin
        • +5 more
        • Brussels, Belgium
        • +100 more
        Dec 12, 2022

        Gastrointestinal Stromal Tumors Trial in Worldwide (Masitinib, Sunitinib)

        Completed
        • Gastrointestinal Stromal Tumors
        • Saint Louis, Missouri
        • +4 more
        Dec 7, 2020

        Progressive Gastrointestinal Stromal Tumor Trial in Germany (Imatinib mesylate)

        Completed
        • Progressive Gastrointestinal Stromal Tumor
        • Imatinib mesylate
        • Berlin, Germany
        • +6 more
        Sep 8, 2020

        Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Canada, United States (Dasatinib, Imatinib Mesylate, Laboratory

        Active, not recruiting
        Has Results
        • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
        • Burbank, California
        • +340 more
        Jan 28, 2023

        Innate CD8+ T Cells and Evolution of Tyrosine Kinase Inhibitor

        Recruiting
        • Leukemia
        • +3 more
        • Phenotyping of total and innate CD8+T cells by flow cytometry
        • Nîmes, Gard, France
          CHU de Nîmes
        Jul 19, 2021

        Gastrointestinal Stromal Tumor of Rectum Trial in Fuzhou (Imatinib Mesylate, Local resection)

        Not yet recruiting
        • Gastrointestinal Stromal Tumor of Rectum
        • Imatinib Mesylate
        • Local resection
        • Fuzhou, Fujian, China
          Weizhong Jiang
        Jul 23, 2023

        CML Trial in Tempe (Imatinib Mesylate, IkT-001Pro)

        Recruiting
        • CML
        • Tempe, Arizona
          Celerion
        Nov 21, 2022

        Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,

        Recruiting
        • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
        • Minimal Residual Disease
        • Goodyear, Arizona
        • +237 more
        Jan 3, 2023

        Sarcoma Trial in Helsinki (Imatinib)

        Recruiting
        • Sarcoma
        • Helsinki, Finland
          Helsinki University Central Hospital
        Sep 26, 2022

        Solid Tumors Trial run by the National Cancer Institute (NCI) (Nilotinib + Paclitaxel)

        Recruiting
        • Solid Tumors
        • Nilotinib + Paclitaxel
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Aug 24, 2022

        Ph+ ALL Trial in China (Olverembatinib, Imatinib)

        Recruiting
        • Ph+ ALL
        • Chongqing, Chongqing, China
        • +8 more
        Sep 22, 2023